Global AL Amyloidosis Market, Global AL Amyloidosis Market Report, Global AL Amyloidosis Market Trends, Global AL Amyloidosis Market Size

AL Amyloidosis Industry Anticipated to Expand at 12.8% CAGR During the Forecast Period

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The AL Amyloidosis Market By 2029?

The al amyloidosis market has experienced rapid expansion in recent years. It is anticipated to increase from $3.11 billion in 2024 to $3.51 billion in 2025, registering a compound annual growth rate (CAGR) of 12.9%. This historical growth can be linked to several factors, including heightened awareness of al amyloidosis among healthcare providers, an increasing incidence of the condition, a rising geriatric population, the expansion of diagnostic centers, and advancements in cardiac imaging.

The al amyloidosis market is projected to experience swift expansion in the coming years. It is anticipated to reach $5.68 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.8%. This growth during the forecast period is attributed to the rising incidences of mutations in blood cell DNA, expanding healthcare infrastructure, an increasing incidence of multiple myeloma, the introduction of combination therapies, and the greater use of high-dose chemotherapy. Significant trends expected in the forecast period include advancements in diagnostic techniques, technological improvements in drug delivery, enhancements in blood tests, the development of targeted therapies, and the adoption of artificial intelligence (AI) in diagnosis.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp

Which Drivers Are Impacting The AL Amyloidosis Market?

The increasing occurrence of plasma cell disorders is anticipated to fuel the expansion of the AL amyloidosis market in the future. These disorders are medical conditions where irregular plasma cells produce an excessive or abnormal amount of antibodies, potentially leading to organ damage. The growing frequency of plasma cell disorders is attributed to elements such as an aging population, longer life expectancies, and advancements in diagnostic technologies. AL amyloidosis emerges from plasma cell disorders, specifically due to the overproduction of atypical light chain proteins. This leads to the accumulation of amyloid deposits in organs and tissues, further intensifying the impact of plasma cell dyscrasias. For instance, in August 2024, as per reports issued by The American Cancer Society (ACS), a US-based nonprofit organization, around 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024 (19,520 in men and 16,260 in women), and approximately 12,540 deaths are projected, comprising 7,020 in men and 5,520 in women. Consequently, the rising incidence of plasma cell disorders is driving the growth of the AL amyloidosis market.

What Are The Emerging Segments Gaining Attention In The AL Amyloidosis Market?

The al amyloidosismarket covered in this report is segmented –

1) By Treatment: Chemotherapy; Supportive Care; Surgery; Stem Cell Transplant; Targeted Therapy

2) By Drugs: Transthyretin Transport Inhibitor; Immunomodulatory Drugs; Monoclonal Antibodies; Proteasome Inhibitors; Other Drugs

3) By Route Of Administration: Intravenous; Oral

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Chemotherapy: Conventional Chemotherapy Agents; High-Dose Chemotherapy

2) By Supportive Care: Pain Management; Organ-specific Supportive Care (Cardiac, Renal)

3) By Surgery: Organ Transplantation; Debulking Surgery

4) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant

5) By Targeted Therapy: Monoclonal Antibodies; Proteasome Inhibitors; Kinase Inhibitors

What Key Innovation Trends Are Fueling Advancements In The AL Amyloidosis Market?

Leading companies in the AL amyloidosis market are prioritizing the development of innovative therapies, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to enhance treatment effectiveness and patient outcomes. Next-generation BCMA-directed CAR T-cell therapy is defined as an advanced form of immunotherapy that modifies a patient’s T cells to identify and attack BCMA on the surface of cancer cells, specifically in multiple myeloma. As an illustration, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical firm, obtained approval from the U.S. Food and Drug Administration (FDA) for NXC-201 to treat the life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201 represents a next-generation CAR-T cell therapy undergoing clinical trials for amyloid light chain (AL) amyloidosis, exhibiting promising results with a 100% hematologic response rate and organ improvements among patients who had not responded to prior treatments.

Which Industry Leaders Are Driving Innovation Across The AL Amyloidosis Market?

Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

Which Region Is Projected To Lead The AL Amyloidosis Market During The Forecast Period?

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The AL Amyloidosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20710&type=smp

Browse Through More Reports Similar to the Global AL Amyloidosis Market 2025, By The Business Research Company

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Plasmas Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/plasmas-therapy-global-market-report

Mycoplasma Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795